Back to all bills
Standard Summary
Comprehensive overview in 1-2 paragraphs
Provides a phase-in discount for plasma-derived products under Medicare Part D manufacturer discount program.
Key Points
- 1Establishes gradual discount reduction for plasma-derived products from 99% to 90% (2026-2030)
- 2Provides steeper phase-down to 80% for products after 2031 for certain beneficiaries
- 3Applies to products marketed as of August 16, 2022
- 4Defines plasma-derived products as biological products from human blood or plasma
- 5Maintains existing protections for small manufacturers and certain drugs
- 6Seeks to preserve access to specialty medicines while managing costs
Impact Areas
Medicare Part D beneficiariesPharmaceutical manufacturersPlasma-derived therapeuticsMedicare program costs
Generated by kwaipilot/kat-coder-pro:free on Nov 19, 2025